8-KEarnings & ResultsLeadership ChangesExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 2, 2011)

Filed May 2, 2011For Securities:ALNY

Summary

This Form 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) on May 2, 2011, primarily serves to report the company's financial results for the quarter ended March 31, 2011. While the specific financial details are provided in an attached press release (Exhibit 99.1), this filing confirms the announcement of these results. Investors should refer to Exhibit 99.1 for a comprehensive understanding of Alnylam's financial performance during the first quarter of 2011, including revenue, expenses, and net income/loss. Additionally, the filing discloses the retirement of Dr. Vicki L. Sato from Alnylam's Board of Directors, effective April 30, 2011. Dr. Sato had been a director since 2005. This change in board composition is a governance update that investors may consider.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its financial results for the first quarter ended March 31, 2011, on May 2, 2011.
  • 2The financial results are detailed in a press release furnished as Exhibit 99.1 to this Form 8-K.
  • 3Dr. Vicki L. Sato retired from the Board of Directors on April 30, 2011.
  • 4Dr. Sato had served as a member of the Board since 2005.
  • 5The filing is primarily an informational update regarding financial results and a director's departure.

Frequently Asked Questions

The detailed financial results for the quarter ended March 31, 2011, are provided in the press release furnished as Exhibit 99.1 to this Form 8-K filing. Investors should refer to that exhibit for specific financial data.

Dr. Vicki L. Sato was a member of Alnylam Pharmaceuticals' Board of Directors since 2005. Her retirement from the Board, effective April 30, 2011, is a governance event that is disclosed in this filing.

This specific Form 8-K filing primarily focuses on the announcement of the first-quarter financial results and the departure of a director. Any strategic updates or product development news would typically be found within the accompanying press release (Exhibit 99.1) or in subsequent SEC filings.